Amarin Corp Plc (AMRN)

[ziploc_1]

Make no mistake...Triple damages would be very important to Amarin....as they might enable Amarin to restart advertisements for Vascepa again...but it would be MUCH MORE IMPORTANT for generics to cease their infringement on Amarin's CVD patent NOW!

Unfortunately neither a settlement with Hikma, nor even treble damages would solve the damage done to Vascepa and to Amarin....In the long run, after Amarin's CVD patent runs out, Vascepa might even prove to be more profitable for generics rather than the paltry sums they are now making from Vascepa.

This is not taking into account the damage that infringement is doing to the health of millions of patients, who have never been able to hear about Vascepa because the financial difficulties of Amarin which are directly due to the infringement policies of the generics.